XML 89 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborations (Tables)
 9 Months Ended
Sep. 30, 2025
Janssen Biotech Inc.  
Collaborative and license agreements  
Schedule of profit and cost sharing relationship
The following table shows the profit and cost sharing relationship between Janssen and AbbVie:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2025202420252024
United States - Janssen's share of profits (included in cost of products sold)$235 $282 $735 $849 
International - AbbVie's share of profits (included in net revenues)199 210 619 676 
Global - AbbVie's share of other costs (included in respective line items)24 38 74 120 
Genentech, Inc.  
Collaborative and license agreements  
Schedule of profit and cost sharing relationship The following table shows the profit and cost sharing relationship between Genentech and AbbVie:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2025202420252024
Genentech's share of profits, including royalties (included in cost of products sold)$286 $263 $790 $733 
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)13 10 26 25 
AbbVie's share of development costs (included in R&D)15 21 47 63